These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11753165)

  • 1. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C.
    Jacobson KR; Murray K; Zellos A; Schwarz KB
    J Pediatr Gastroenterol Nutr; 2002 Jan; 34(1):52-8. PubMed ID: 11753165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
    Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
    [No Abstract]   [Full Text] [Related]  

  • 3. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms.
    Gordon CE; Uhlig K; Lau J; Schmid CH; Levey AS; Wong JB
    Am J Kidney Dis; 2008 Feb; 51(2):263-77. PubMed ID: 18215704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
    Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S
    Digestion; 2000; 61(2):90-7. PubMed ID: 10705172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-treatment of children with chronic hepatitis C who did not respond to interferon-alpha treatment.
    Gerner P; Hilbich J; Wenzl TG; Behrens R; Walther F; Kliemann G; Enninger A; Wirth S
    J Pediatr Gastroenterol Nutr; 2010 Aug; 51(2):187-90. PubMed ID: 20512050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
    Lamers MH; Broekman M; Drenth JP; Gluud C
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD011132. PubMed ID: 24937404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.
    Sjogren MH; Sjogren R; Holtzmuller K; Winston B; Butterfield B; Drake S; Watts A; Howard R; Smith M
    Dig Dis Sci; 2005 Apr; 50(4):727-32. PubMed ID: 15844709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a.
    Tabaru A; Narita R; Hiura M; Abe S; Otsuki M
    Am J Gastroenterol; 2005 Apr; 100(4):862-7. PubMed ID: 15784033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
    AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of interferon alfa and ribavirin treatment on hepatitis C virus RNA in serum and peripheral blood mononuclear cells in children with chronic hepatitis C.
    Majda-Stanisławska E; Bednarek M; Jóźwiak B; Sidorkiewicz M; Piekarska A; Kuydowicz J
    Acta Gastroenterol Belg; 2006; 69(2):187-90. PubMed ID: 16929613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alpha treatment of chronic hepatitis C virus infection in children.
    Jonas MM; Ott MJ; Nelson SP; Badizadegan K; Perez-Atayde AR
    Pediatr Infect Dis J; 1998 Mar; 17(3):241-6. PubMed ID: 9535253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoadamantanes for chronic hepatitis C.
    Lamers MH; Broekman M; Drenth JP; Gluud C
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD010125. PubMed ID: 24793264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary results of individual therapy of chronic hepatitis C by Ukrain and interferon-alpha.
    Voltchek I; Sologub T; Nowicky JW; Grigoryeva T; Belozyorova L; Belopolskaya M; Semenyako N; Lamanova E
    Drugs Exp Clin Res; 2000; 26(5-6):261-6. PubMed ID: 11345036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C.
    Thuluvath PJ; Maheshwari A; Mehdi J; Fairbanks KD; Wu LL; Gelrud LG; Ryan MJ; Anania FA; Lobis IF; Black M
    Gut; 2004 Jan; 53(1):130-5. PubMed ID: 14684587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial.
    Xie Y; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
    Hepatobiliary Pancreat Dis Int; 2005 May; 4(2):213-9. PubMed ID: 15908318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
    Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.